SpinalCyte was issued Canadian patent No. 2,925,550, "Methods and Compositions for Repair of Cartilage Using an In Vivo Bioreactor," related to subjecting fibroblast cells to specific environments so that they will differentiate into chondrocytes for use in joints and spinal discs.
The company's intellectual property portfolio comprises 37 U.S. and international patents issued and 100+ patents pending focused on fibroblast technologies. An Investigational New Drug clearance from FDA in 2018 allows SpinalCyte to continue clinical trials of CybroCell in the treatment of degenerative disc disease (DDD).
CybroCell is an off-the-shelf allogenic human dermal fibroblast product. SpinalCyte's Phase I/II clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated that, after 12 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
Sources: SpinalCyte, LLC; ORTHOWORLD Inc.